Second malignancy in advanced or recurrent non‐small cell lung cancer after the advent of molecular targeted drugs and immunotherapy
This study found that 8.9% of patients with advanced NSCLC who received TKIs, ICIs, or immune combination therapy and survived ≥2 years developed secondary malignancies. This underscores the importance of early diagnosis and treatment, even during lung cancer treatment, to identify suspicious lesions in other organs either via imaging or physical examinations.
Authors
- H Shiozaki
- Shoko Shimamura
- Ken Tajima (ORCID: https://orcid.org/0000-0003-1688-0287)
- Takehito Shukuya (ORCID: https://orcid.org/0000-0002-0972-4692)
- Yoichiro Mitsuishi (ORCID: https://orcid.org/0000-0001-7040-6653)
- Tomoyasu Mimori
- Shunichi Kataoka
- Yoshihiro Masui (ORCID: https://orcid.org/0009-0008-2886-6638)
- Kana Kurokawa (ORCID: https://orcid.org/0000-0001-9129-4718)
- Ikuko Nakamura
- Naoko Shimada
- Tetsuhiko Asao (ORCID: https://orcid.org/0000-0002-9975-2282)
- Yoshika Koinuma
- Kazuhisa Takahashi
- Taichi Miyawaki
- Ryota Kanemaru
Institutions
- Juntendo University (JP)
Publication Details
- Journal
- Thoracic Cancer
- Published
- 2024-10-07
- DOI
- https://doi.org/10.1111/1759-7714.15457
- Citations
- 2
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.84